Participant flow18

How many started, completed or left each group, period by period.

1 to 18 of 18

Period	Milestone	Group	Participants
Double-Blind Phase	STARTED	Sirolimus 0.2%	7
Double-Blind Phase	STARTED	Sirolimus 0.4%	8
Double-Blind Phase	STARTED	Placebo	9
Double-Blind Phase	COMPLETED	Sirolimus 0.2%	7
Double-Blind Phase	COMPLETED	Sirolimus 0.4%	8
Double-Blind Phase	COMPLETED	Placebo	9
Double-Blind Phase	NOT COMPLETED	Sirolimus 0.2%	0
Double-Blind Phase	NOT COMPLETED	Sirolimus 0.4%	0
Double-Blind Phase	NOT COMPLETED	Placebo	0
Open-label Phase	STARTED	Sirolimus 0.2%	7
Open-label Phase	STARTED	Sirolimus 0.4%	8
Open-label Phase	STARTED	Placebo	9
Open-label Phase	COMPLETED	Sirolimus 0.2%	6
Open-label Phase	COMPLETED	Sirolimus 0.4%	6
Open-label Phase	COMPLETED	Placebo	7
Open-label Phase	NOT COMPLETED	Sirolimus 0.2%	1
Open-label Phase	NOT COMPLETED	Sirolimus 0.4%	2
Open-label Phase	NOT COMPLETED	Placebo	2

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03363763/flow